血液系统恶性肿瘤中的PI3K抑制剂 - Suppr

Suppr

超能文献

PI3K inhibitors in haematological malignancies.

作者信息

Matasar Matthew J, Hiemeyer Florian, Childs Barrett H, Zinzani Pier Luigi

机构信息

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Clinical Statistics, Bayer AG, Berlin, Germany.

出版信息

Lancet Oncol. 2022 Aug;23(8):e365. doi: 10.1016/S1470-2045(22)00332-1.

DOI:10.1016/S1470-2045(22)00332-1

PMID:35901826

Abstract

摘要

相似文献

PI3K inhibitors in haematological malignancies.

Lancet Oncol. 2022 Aug;23(8):e365. doi: 10.1016/S1470-2045(22)00332-1.

PI3K inhibitors in haematological malignancies.

Lancet Oncol. 2022 Aug;23(8):e364. doi: 10.1016/S1470-2045(22)00300-X.

PI3K inhibitors in haematological malignancies.

Lancet Oncol. 2022 Aug;23(8):e362-e363. doi: 10.1016/S1470-2045(22)00260-1.

The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.

Lancet Oncol. 2022 May;23(5):563-566. doi: 10.1016/S1470-2045(22)00200-5. Epub 2022 Apr 14.

Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition.

Br J Haematol. 2015 Jul;170(2):275-8. doi: 10.1111/bjh.13283. Epub 2015 Jan 12.

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.

Haematologica. 2014 Jan;99(1):7-18. doi: 10.3324/haematol.2013.087171.

PI3K as a target for therapy in haematological malignancies.

Curr Top Microbiol Immunol. 2010;347:169-88. doi: 10.1007/82_2010_71.

The role and therapeutic implications of PI3K signaling pathway in cancer.

J Surg Oncol. 2021 Jan;123(1):39-41. doi: 10.1002/jso.26296. Epub 2020 Nov 12.

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.

Curr Treat Options Oncol. 2006 Jul;7(4):285-94. doi: 10.1007/s11864-006-0038-1.

PI3K Isoform-Selective Inhibitors in Cancer.

Adv Exp Med Biol. 2020;1255:165-173. doi: 10.1007/978-981-15-4494-1_14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

PI3K inhibitors in haematological malignancies.

Lancet Oncol. 2022 Aug;23(8):e365. doi: 10.1016/S1470-2045(22)00332-1.

PI3K inhibitors in haematological malignancies.

Lancet Oncol. 2022 Aug;23(8):e364. doi: 10.1016/S1470-2045(22)00300-X.

PI3K inhibitors in haematological malignancies.

Lancet Oncol. 2022 Aug;23(8):e362-e363. doi: 10.1016/S1470-2045(22)00260-1.

The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.

Lancet Oncol. 2022 May;23(5):563-566. doi: 10.1016/S1470-2045(22)00200-5. Epub 2022 Apr 14.

Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition.

Br J Haematol. 2015 Jul;170(2):275-8. doi: 10.1111/bjh.13283. Epub 2015 Jan 12.

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies.

Haematologica. 2014 Jan;99(1):7-18. doi: 10.3324/haematol.2013.087171.

PI3K as a target for therapy in haematological malignancies.

Curr Top Microbiol Immunol. 2010;347:169-88. doi: 10.1007/82_2010_71.

The role and therapeutic implications of PI3K signaling pathway in cancer.

J Surg Oncol. 2021 Jan;123(1):39-41. doi: 10.1002/jso.26296. Epub 2020 Nov 12.

Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies.

Curr Treat Options Oncol. 2006 Jul;7(4):285-94. doi: 10.1007/s11864-006-0038-1.

PI3K Isoform-Selective Inhibitors in Cancer.

Adv Exp Med Biol. 2020;1255:165-173. doi: 10.1007/978-981-15-4494-1_14.

PI3K inhibitors in haematological malignancies.

作者信息

Matasar Matthew J, Hiemeyer Florian, Childs Barrett H, Zinzani Pier Luigi

机构信息

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Clinical Statistics, Bayer AG, Berlin, Germany.

出版信息

Lancet Oncol. 2022 Aug;23(8):e365. doi: 10.1016/S1470-2045(22)00332-1.

DOI:10.1016/S1470-2045(22)00332-1

PMID:35901826

Abstract

摘要